Aethlon Medical (AEMD) said Monday that the first patient has been enrolled in an Australian clinical trial of its immunotherapeutic device Hemopurifier to treat patients with solid tumors.
The company said the trial will treat patients who have stable or progressive disease while receiving anti-PD-1 monotherapy, such as Keytruda or Opdivo.
Aethlon said the first patient will receive anti-PD-1 therapy within the next two months, when concentrations of extracellular vesicles and anti-tumor T cell activity will be measured.
Shares of Aethlon Medical were up 14% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments